Delving into the Latest Updates on Hunan Siweikang Pharmaceutical Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Hemic and Lymphatic Diseases

Immune System Diseases

CAR-T

Autologous CAR-T

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	5
Hemic and Lymphatic Diseases	4
Immune System Diseases	3
Nervous System Diseases	1

Top 5 Drug Type	Count

CAR-T	4
Autologous CAR-T	1

Top 5 Target	Count

EGFRvIII(Epidermal growth factor receptor variant III)	1
CD123(Interleukin-3 receptor subunit alpha)	1
CD22	1
BCMA x CD19	1
CD19(B-lymphocyte antigen CD19)	1

在中国复发或难治性多发性骨髓瘤患者中静脉给予不同剂量的SWK001注射液，评价药物的耐受性、安全性，并从安全性角度确定确证性临床研究推荐剂量。在中国复发或难治性多发性骨髓瘤患者中静脉给予SWK001注射液，从生产和受试者状态两方面，评价该CAR-T治疗方案的可行性。

[Translation]

Different doses of SWK001 injection were administered intravenously to Chinese patients with relapsed or refractory multiple myeloma to evaluate the tolerability and safety of the drug, and determine the recommended dose for confirmatory clinical studies from a safety perspective. SWK001 injection was administered intravenously to Chinese patients with relapsed or refractory multiple myeloma to evaluate the feasibility of this CAR-T treatment regimen from the perspectives of production and subject status.

Start Date14 Mar 2024

Sponsor / Collaborator

Hunan Siweikang Pharmaceutical Co., Ltd.

100 Clinical Results associated with Hunan Siweikang Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Hunan Siweikang Pharmaceutical Co., Ltd.

Login to view more data

100 Deals associated with Hunan Siweikang Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Hunan Siweikang Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 19 Dec 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

4

1

Phase 1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Anti-BCMAxCD19 CAR-T(Hunan Siweikang) ( BCMA x CD19 )	Multiple Myeloma More	Phase 1
CD22-CART(Siweikang Pharmaceutical) ( CD22 )	Acute Lymphoblastic Leukemia More	Preclinical
CD19-CART(Siweikang Pharmaceutical) ( CD19 )	Lymphoid Leukemia More	Preclinical
CD123-CART(Siweikang Pharmaceutical) ( CD123 )	Acute Myeloid Leukemia More	Preclinical
EGFRVIII-CART(Siweikang Pharmaceutical) ( EGFRvIII )	Glioblastoma More	Preclinical